Workflow
SHANGHAI KAIBAO(300039)
icon
Search documents
上海凯宝(300039) - 2015年4月28日投资者关系活动记录表
2022-12-08 02:18
证券代码:300039 证券简称:上海凯宝 记录编号:2015-002 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------|---------------------------|--------------|----------------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | 投资者关 | □媒体采访 □业绩说明会 | | | | 系 | □ 新闻发布会 □路演活动 | | | | 活动类别 | | | □现场参观 □其他 (请文字说明其他活动内容) | | | | | | | 参与单位 名称及人 | | | 证券日报——周一叶 甘玲玉 上海申辰——冯超 | | 员姓名 | | | | | | | | | | 时 间 | 2015 年 04 月 | 28 日 上午 | 14:30 -15:30 | | 地 点 | 公司二楼会议室 | | | | 上市公司 | | | | | 接待人员 | 董秘: ...
上海凯宝(300039) - 2015年5月18日投资者关系活动记录表
2022-12-08 01:58
证券代码:300039 证券简称:上海凯宝 记录编号:2015-003 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |----------|---------------------------|-----------------|-------|----------------------------------------------------------|----------------------------------------------------------------| | | √特定对象调研 □分析师会议 | | | | | | 投资者关 | □媒体采访 □业绩说明会 | | | | | | 系 | □ 新闻发布会 □路演活动 | | | | | | 活动类别 | | | | □现场参观 □其他 (请文字说明其他活动内容) | | | | | | | | | | | | | | 信达澳银基金——曾国富 张培培 安信证券---于洋 国信证券 --- | 万明亮 | | | 东方证券 ---- | 黄文锋 红象投 ...
上海凯宝(300039) - 2014年11月19日投资者关系活动记录表
2022-12-07 09:44
编号:2014-008 证券代码:300039 证券简称:上海凯宝 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|---------------------------|------------------------------------------------------------------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系 | □ | 媒体采访 □业绩说明会 | | 活动类别 | □ | 新闻发布会 □路演活动 | | | □ | 现场参观 □其他 (请文字说明其他活动内容) | | | | 德威资本-樊学栋 太平资产-岳雄伟 嘉实基金-董理 东方基金-邱 | | | | 义鹏 中信建投证券-杨扬 张芳 黄健 淡水泉投资-叶智深 郑晓刚 中 | | | | 海基金-俞中华 青溪资产-郝结旺 太平资产-朱云 国泰君安-王超 | | 参与单位名称及 | | 伟 长 ...
上海凯宝(300039) - 2015年05月28日投资者关系活动记录表
2022-12-07 08:28
证券代码:300039 证券简称:上海凯宝 记录编号:2015-004 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------|--------------------------------|----------------------------------------------------------------------| | | | | | | | √特定对象调研 □分析师会议 | | 投资者关 | □媒体采访 □业绩说明会 | | | 系 | □ | 新闻发布会 □路演活动 | | 活动类别 | | □现场参观 □其他 (请文字说明其他活动内容) | | | | | | | 上海申银万国证券 | ---- 周子露 财通基金---赵吉龙 中国国籍证券 --- 李冠一 | | 参与单位 | 华泰长城资本 ---- | 张微 申万宏源研究---罗佳荣 上海益研投资 --- 茆建胜 | | 名称及人 | 上海混沌道然资产—周宇 汇丰晋信 | ---- 段炼炼 唐亮 元大宝来投信 --- 刘家宏 | | 员姓名 | 凯基投资 --- ...
上海凯宝(300039) - 2017年6月13日投资者关系活动记录表
2022-12-06 05:36
证券代码:300039 证券简称:上海凯宝 记录编号:2017-002 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|-------------------------|------------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 (请文字说明其他活动内容) | | | | | | 参与单位 | | | | 名称及人 | 方泉投资 | | | 员姓名 | | | | 时 间 | 2017 年 6 月 13 | 日 下午 14:00 -15 : 30 | | | | | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | 董 秘:穆竟伟 | | | 姓名 | | | | 投资者关 | 1 、公司近期业绩回顾 | | | 系活动主 | | | ...
上海凯宝(300039) - 2016年11月10日投资者关系活动记录表
2022-12-06 01:33
证券代码:300039 证券简称:上海凯宝 记录编号:2016-002 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|--------------------------------|----------------------------------------------------------------------| | | √ 特定对象调研 □分析师会议 | | | 投资者关 | □ 媒体采访 □业绩说明会 | | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 (请文字说明其他活动内容) | | | | | | 参与单位 | | | | 名称及人 | 安信证券、郎晨投资 | | | 员姓名 | | | | 时 间 | 2016 年 11 月 10 | 日 下午 13:30 -15:00 | | | | | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | 董 秘:穆竟伟 财务总监:任立旺 | | | 姓名 | | | | 投资者关 | 1 、介绍公司基本情况 ...
上海凯宝(300039) - 2017年9月25日投资者关系活动记录表
2022-12-05 01:56
证券代码:300039 证券简称:上海凯宝 记录编号:2017-004 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|------------------------|-------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ 新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 (请文字说明其他活动内容) | | --- | --- | |----------|------------------------------------------------------------------| | | | | 参与单位 | | | 名称及人 | 凯峰资本 | | 员姓名 | | | 时 间 | 2017 年 9 月 25 日 下午 2: 30 -4:00 | | 地 点 | 公司二楼会议室 | | 上市公司 | | | 接待人员 | 董 秘:穆竟伟 证券部:马聪 ...
上海凯宝(300039) - 2017年8月23日投资者关系活动记录表
2022-12-05 01:50
证券代码:300039 证券简称:上海凯宝 记录编号:2017-003 上海凯宝药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|-------------------------|------------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关 | □ | 媒体采访 □业绩说明会 | | 系 | □ | 新闻发布会 □路演活动 | | 活动类别 | □ | 现场参观 □其他 (请文字说明其他活动内容) | | | | | | 参与单位 | | | | 名称及人 | | 中金公司、财通证券、承珞资本、 | | 员姓名 | | | | 时 间 | 2017 年 8 月 23 | 日 上午 10: 30 -12:00 | | 地 点 | 公司二楼会议室 | | | 上市公司 | | | | 接待人员 | | 董 秘:穆竟伟 证券部:马聪影 | | 姓名 | | | | 投资者关 | | 一、董秘穆竟伟女士简单介绍公司基本情况 | | ...
上海凯宝(300039) - 2022 Q3 - 季度财报
2022-10-25 16:00
Financial Performance - The company's revenue for Q3 2022 was ¥259,841,333.60, representing a 1.14% increase year-over-year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥35,835,359.96, up 6.31% compared to the same period last year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥34,405,017.31, reflecting a significant increase of 21.88% year-over-year[7]. - Total operating revenue for the current period reached ¥800,013,064.85, a slight increase from ¥794,949,444.36 in the previous period, representing a growth of approximately 1.34%[30]. - Net profit for the current period was ¥118,044,013.52, compared to ¥115,498,710.67 in the previous period, indicating an increase of approximately 2.14%[30]. - Other comprehensive income after tax for the current period was ¥585,310,000.00, compared to ¥373,137,500.00 in the previous period, reflecting an increase of approximately 56.8%[32]. - The total comprehensive income for the current period was ¥703,354,013.52, compared to ¥488,636,210.67 in the previous period, indicating a growth of about 43.9%[32]. Cash Flow and Investments - The operating cash flow net amount for the year-to-date period increased by 129.99%, totaling ¥236,316,100.08[7]. - Net cash flow from operating activities decreased by 135.05% year-over-year, mainly due to increased investment activities[16]. - Cash inflow from operating activities totaled ¥1,008,773,655.28, up from ¥963,717,206.74, representing an increase of approximately 4.7%[33]. - Cash inflow from investment activities totaled $2.47 billion, compared to $1.46 billion in the prior period, indicating strong investment recovery[36]. - Net cash outflow from investment activities was $197.78 million, a decline from a positive cash flow of $3.72 million previously, suggesting increased investment expenditures[36]. - Cash inflow from the recovery of investments was $2.07 billion, significantly higher than $1.32 billion in the previous period, highlighting effective investment strategies[36]. - The company made cash payments for investments totaling $2.13 billion, compared to $1.31 billion previously, indicating aggressive investment in growth opportunities[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,156,931,861.21, a 23.87% increase from the end of the previous year[7]. - The company's total current assets as of September 30, 2022, amount to CNY 2,357,412,713.73, an increase from CNY 2,254,417,970.03 at the beginning of the year[21]. - The total non-current assets increased to CNY 1,799,519,147.48 from CNY 1,101,398,799.74[24]. - The total liabilities increased to ¥460,966,028.56 from ¥310,904,950.64, showing a significant rise of approximately 48.3%[30]. - The total liabilities include short-term borrowings of CNY 81,910,127.65 and accounts payable of CNY 75,015,901.66[24]. Shareholder Information - Shareholders' equity attributable to the parent company was ¥3,696,536,519.48, marking a 21.40% increase compared to the previous year[7]. - The total number of common shareholders at the end of the reporting period is 58,608, with the top ten shareholders holding significant stakes[17]. - The largest shareholder, Mu Jingwei, holds 16.06% of the shares, amounting to 168,029,270 shares[17]. Operational Costs and Expenses - Total operating costs decreased to ¥660,043,298.28 from ¥663,967,428.89, reflecting a reduction of about 0.44%[30]. - Research and development expenses rose to ¥36,092,230.66 from ¥31,986,225.60, marking an increase of about 12.6%[30]. - The company paid $173.05 million to employees, an increase from $162.09 million, reflecting higher operational costs[36]. - Cash outflow related to other operating activities was $370.61 million, down from $408.61 million, showing improved cost management[36]. Government Support - The company received government subsidies amounting to ¥3,159,357.91 during the reporting period[8]. Miscellaneous - The company has not disclosed any new strategies or future outlook in the provided documents[19].